Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in Soft Tissue Sarcoma
NCT05142631Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in soft tissue sarcoma (STS), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 months. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05142631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142631.